A. Moccia, Bellinzona (Switzerland), et al.
PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK)
Authors Conclusion from the abstract: We provided the first validation in an independent cohort of the recent observation that POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful endpoint for the future evaluation of novel chemotherapy‐free strategies.
F. Morschhauser, Lille (France), et al.
Authors Conclusion from the abstract: CR rate at EOI for the chemo‐free regimen G‐LEN‐atezo is comparable with currently available treatment options in this indication and higher than with historical controls, with durable activity. The overall safety and tolerability profile is consistent with the known profiles for the individual drugs and for G‐LEN.
J.P. Leonard, New York, NY (USA), et al.
Authors Conclusion from the abstract: R2 demonstrated superior efficacy over R/placebo in patients with FL grade 1‐3a, including those with POD24, patients who have historically been associated with worse outcomes.
J. Sharman, Eugene, OR (USA), et al.
Authors Conclusion from the abstract: R2 therapy is an active treatment regimen in patients with R/R FL grade 1‐3a and MZL, including patients who were refractory to rituximab, and with a tolerable safety profile.
M.H. Delfau-Larue, Creteil (France), et al.
Authors Conclusion from the abstract: In agreement with the clinical results of RELEVANCE trial, our results show that an immunomodulatory induction treatment in first line FL can achieves high rate of MR in both blood and bone marrow; Achieving a complete MR at the end of induction was predicting a more favorable PFS.
A. Stathis, Bellinzona (Switzerland), et al.
Authors Conclusion from the abstract: This is the first study to assess obinutuzumab plus venetoclax in untreated advanced FL in need of systemic therapy. The two drugs could be safely combined and may represent a valuable chemotherapy‐free regimen. The RP2D is venetoclax 800mg OD continuously for 6 cycles starting on d 2 of cycle 1 in combination with obinutuzumab 1000mg on d 1,8,15 of cycle 1 and on d 1 of cycles 2‐6, followed by obinutuzumab maintenance for up to two years. Preliminary data show promising activity and updated results will be presented.